Monographie - Filgrastim - Stabilis 4.0

Ultimo aggiornamento :
19/11/2024

Altro

Filgrastim

Iniezione

Stabilità in soluzione

Stabilità in miscela

Fattori che influenzano la stabilità

Compatibilità

metodo di iniezione

Bibliografia

pdf

Nome commerciale

Nome commerciale

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Accofil	Belgio, Germania, Gran Bretagna
Biocilin	Messico
Duperan	Chile
Filgen	Argentina
Foltran	Chile
Granulokine	Grecia, Italia
Hebervital	Colombia
Inmunef	Colombia
Leucosos	Colombia
Lioplim	Chile
Neupogen	Africa del Sud, Austria, Belgio, Croazia, Danimarca, Finlandia, Francia, Gran Bretagna, Paesi Bassi, Polonia, Portogallo, Slovenia, Spagna, Stati Uniti d’America, Svezia, Svizzera, Turchia
Neutromax	Argentina
Neutropine	Argentina
Nivestim	Belgio, Francia, Germania, Gran Bretagna, Norvegia, Paesi Bassi
Ratiograstim	Austria, Germania, Gran Bretagna, Svezia
Tevagrastim	Germania, Gran Bretagna, Norvegia, Paesi Bassi, Svezia, Svizzera

Bibliografia

Iniezione

Bibliografia : Filgrastim

	tipo	pubblicazione
99	Rivista	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
104	Rivista	Hall PD, Yui D, Lyons S, Bosso JA. Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 185-189.
182	Rivista	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Rivista	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
2269	Rivista	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3128	Laboratorio	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3249	Rivista	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3256	Rivista	Burnett B, Radic I. Stability of Hospira filgrastim following changes to thermal and photic storage conditions. EJHP 2011 ; 17, 5: 49-56.
3474	Laboratorio	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3618	Laboratorio	Filgrastim (Neupogen®) - Summary of Product Characteristics Amgen 2014
3828	poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Rivista	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4380	Laboratorio	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4471	Laboratorio	Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019
4521	Rivista	Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020
4650	Laboratorio	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021

Mentions Légales